Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology.
The post Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer appeared first on MedCity News.
